Phillyrin alleviates Kawasaki disease-induced lung inflammation by inhibiting platelet production through the NLRP3/IL-1β/NF-E2 signaling pathway

Key Points

• This research aims to evaluate the therapeutic effects of phillyrin on lung inflammation induced by Kawasaki disease.
• Utilized LCWE to induce lung inflammation in a model.
• Measured the levels of megakaryocyte-derived platelets.
• Assessed the suppression of the NLRP3/IL-1β signaling pathway.
• Analyzed the expression of NF-E2 in lung tissues.
• Phillyrin significantly reduced lung inflammation caused by LCWE.
• It suppressed the production of megakaryocyte-derived platelets.
• Inhibition of the NLRP3/IL-1β signaling pathway was observed.
• Reduced NF-E2 expression linked to decreased thrombopoiesis.